Ari Chong

Ari Chong

Auto-generated profile, based on publicly available information

Ari Chong

Department of Nuclear Medicine, Chosun University Hospital, Gwangju, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DNDinh-Huy Nguyen
Dinh-Huy Nguyen
ACAri Chong
Ari Chong
YHYeongjin Hong
Yeongjin Hong
YHYeongjin Hong
Yeongjin Hong
Here, we provide a brief overview of the approaches and strategies underlying bacteria-based cancer immunotherapy (BCiT). We also describe and summarize research in the field of synthetic biology, which aims to regulate bacterial growth and gene expression for immunotherapeutic use. Finally, we discuss the current clinical status and limitations of BCiT.

16 August 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KCKyu Yeong Choi
Kyu Yeong Choi
JLJang Jae Lee
Jang Jae Lee
TGTAMIL INIYAN GUNASEKARAN
TAMIL INIYAN GUNASEKARAN
SKSarang Kang
Sarang Kang
WLWooje Lee
Wooje Lee
AIAlzheimer’s Disease Neuroimaging Initative
Alzheimer’s Disease Neuroimaging Initative
Variants in the APOE gene region may explain ethnic differences in the association of Alzheimer’s disease (AD) with ε4. Ethnic differences in allele frequencies for three APOE region SNPs (single nucleotide polymorphisms) were identified and tested for association in 19,398 East Asians (EastA), including Koreans and Japanese, 15,836 European ancestry (EuroA) individuals, and 4985 African Americans, and with brain imaging measures of cortical atrophy in sub-samples of Koreans and EuroAs. Among ε4/ε4 individuals, AD risk increased substantially in a dose-dependent manner with the number of APOE promoter SNP rs405509 T alleles in EastAs (TT: OR (odds ratio) = 27.02, p = 8.80 × 10−94; GT: OR = 15.87, p = 2.62 × 10−9) and EuroAs (TT: OR = 18.13, p = 2.69 × 10−108; GT: OR = 12.63, p = 3.44 × 10−64), and rs405509-T homozygotes had a younger onset and more severe cortical atrophy than those with G-allele. Functional experiments using APOE promoter fragments demonstrated that TT lowered APOE expression in human brain and serum. The modifying effect of rs405509 genotype explained much of the ethnic variability in the AD/ε4 association, and increasing APOE expression might lower AD risk among ε4 homozygotes.

2 May 2024 in Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
SKSeung Kwan Kang
Seung Kwan Kang
MHMina Heo
Mina Heo
JCJi Yeon Chung
Ji Yeon Chung
DKDaewoon Kim
Daewoon Kim
SSSeong A. Shin
Seong A. Shin
Jae Sung LeeJae Sung Lee
Jae Sung Lee
Purpose: This study assesses the clinical performance of BTXBrain-Amyloid, an artificial intelligence-powered software for quantifying amyloid uptake in brain PET images. Methods: 150 amyloid brain PET images were visually assessed by experts and categorized as negative and positive. Standardized uptake value ratio (SUVR) was calculated with cerebellum grey matter as the reference region, and receiver operating characteristic (ROC) and precision-recall (PR) analysis for BTXBrain-Amyloid were conducted. For comparison, same image processing and analysis was performed using Statistical Parametric Mapping (SPM) program. In addition, to evaluate the spatial normalization (SN) performance, mutual information (MI) between MRI template and spatially normalized PET images was calculated and SPM group analysis was conducted. Results: Both BTXBrain and SPM methods discriminated between negative and positive groups. However, BTXBrain exhibited lower SUVR standard deviation (0.06 and 0.21 for negative and positive, respectively) than SPM method (0.11 and 0.25). In ROC analysis, BTXBrain had an AUC of 0.979, compared to 0.959 for SPM, while PR curves showed an AUC of 0.983 for BTXBrain and 0.949 for SPM. At the optimal cut-off, the sensitivity and specificity were 0.983 and 0.921 for BTXBrain and 0.917 and 0.921 for SPM12, respectively. MI evaluation also favored BTXBrain (0.848 vs. 0.823), indicating improved SN. In SPM group analysis, BTXBrain exhibited higher sensitivity in detecting basal ganglia differences between negative and positive groups. Conclusion: BTXBrain-Amyloid outperformed SPM in clinical performance evaluation, also demonstrating superior SN and improved detection of deep brain differences. These results suggest the potential of BTXBrain-Amyloid as a valuable tool for clinical amyloid PET image evaluation.

13 October 2023 in Thyroid®
Verified
Journal Article
Closed access
JBJi-In Bang
Ji-In Bang
SPSohyun Park
Sohyun Park
KKKeunyoung Kim
Keunyoung Kim
YSYoungduk Seo
Youngduk Seo
ACAri Chong
Ari Chong
SOSo Won Oh
So Won Oh
Background: The objective of this study is to evaluate the diagnostic accuracy of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in detecting recurrence in patients with differentiated thyroid cancer (DTC) who have negative whole-body scans (WBSs) but elevated serum thyroglobulin (Tg) or thyroglobulin antibody (TgAb) levels. Methods: This systematic review/meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy criteria (International Prospective Register of Systematic Reviews registration number: CRD42022340924). A comprehensive search of the MEDLINE, EMBASE, and Cochrane databases identified articles reporting the diagnostic accuracy of FDG PET/CT for the detection of recurrence in patients with DTC with negative WBS and elevated serum Tg or TgAb levels published between January 2012 and June 2023. Meta-analyses were performed to determine the diagnostic accuracy of FDG PET/CT on the total target population as well as on subgroups stratified by serum Tg or TgAb, and thyrotropin (TSH) stimulation status at the time of FDG PET/CT. The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework was applied to evaluate the quality of evidence and the strength of recommendations to facilitate translation of the meta-analysis results into practical recommendations for clinical guidelines. Results: A total of 24 studies involving 1988 patients were included for analysis. The overall pooled sensitivity and specificity values were 0.87 (95% confidence interval [CI] = 0.83–0.92; I 2 = 75%) and 0.84 (CI = 0.80–0.89; I 2 = 44%), respectively. Subgroup analyses revealed no significant differences in the diagnostic accuracy of FDG PET/CT in patients stratified by serum Tg or TgAb levels, and TSH stimulation status at the time of PET/CT. Treatment plans were changed following FDG PET/CT imaging in 40% (CI = 34–47%; I 2 = 39%) of cases. The quality level of evidence for using FDG PET/CT was moderate in both sensitivity and specificity according to the GRADE system. Conclusion: There is moderate quality evidence demonstrating the high diagnostic accuracy of FDG PET/CT in detecting recurrence in patients with DTC with negative WBS and elevated serum Tg or TgAb levels. This evidence corroborates the current guidelines' endorsement of FDG PET/CT as a diagnostic tool in such patients.

30 May 2024 in International Journal of Thyroidology
Verified
Journal Article
Open access
PDF file
YPYoung Joo Park
Young Joo Park
ELEun Kyung Lee
Eun Kyung Lee
YSYOUNG SHIN SONG
YOUNG SHIN SONG
BKBon Seok Koo
Bon Seok Koo
HKHyungju Kwon
Hyungju Kwon
CACancer
Cancer
Young Joo Park, Eun Kyung Lee, Young Shin Song, Bon Seok Koo, Hyungju Kwon, Keunyoung Kim, Mijin Kim, Bo Hyun Kim, Won Gu Kim, Won Bae Kim, Won Woong Kim, Jung-Han Kim, Hee Kyung Kim, Hee Young Na, Shin Je Moon, Jung-Eun Moon, Sohyun Park, Jun-Ook Park, Ji-In Bang, Kyorim Back, Youngduk Seo, Dong Yeob Shin, Su-Jin Shin, Hwa Young Ahn, So Won Oh, Seung Hoon Woo, Ho-Ryun Won, Chang Hwan Ryu, Jee Hee Yoon, Ka Hee Yi, Min Kyoung Lee, Sang-Woo Lee, Seung Eun Lee, Sihoon Lee, Young Ah Lee, Joon-Hyop Lee, Ji Ye Lee, Jieun Lee, Cho Rok Lee, Dong-Jun Lim, Jae-Yol Lim, Yun Kyung Jeon, Kyong Yeun Jung, Ari Chong, Yun Jae Chung, Chan Kwon Jung, Kwanhoon Jo, Yoon Young Cho, A Ram Hong, Chae Moon Hong, Ho-Cheol Kang, Sun Wook Kim, Woong Youn Chung, Do Joon Park, Dong Gyu Na, Korean Thyroid Association Guideline Committee on the Managements of Thyroid Nodule and Cancer. Int J Thyroidol 2024;17:1-20. https://doi.org/10.11106/ijt.2024.17.1.1

1 August 2014 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
ACAri Chong
Ari Chong
JHJung-Min Ha
Jung-Min Ha
RHRan Hong
Ran Hong
SPSang-Gon Park
Sang-Gon Park
HLHee Jeong Lee
Hee Jeong Lee
A 59-year-old man underwent abdominal CT for evaluation of weight loss and generalized weakness. A large mass protruding from the lesser curvature of the stomach suggestive of gastrointestinal stromal tumor was demonstrated. F-FDG PET/CT showed hypermetabolic activity in the gastric mass. Mass excision and wedge resection were performed, and the diagnosis of inflammatory myofibroblastic tumor was confirmed.